Six studies were included (n=2,966, range 119 to 1,552): two randomised controlled trials (RCTs), four retrospective studies and one unspecified study design.
Rates of procedural myocardial infarction were 3.73% in the statin group and 9.17% in the control group. Results showed a statistically significant benefit for patients treated with statins. Pooled absolute difference between groups was -5.44% (95% CI -8.2% to -2.7%) and relative risk reduction was 59.3% (95% CI -8.2% to -2.7%). There was no evidence of statistically significant heterogeneity.
Rate of MACE was 15.5% in the statin group and 19.5% in the control group (three trials, n=6,723, range 119 to 5,052). There was no statistically significant difference between groups. Pooled absolute difference was -4.0% (95% CI -11.4% to 3.4%) and relative risk reduction was 20.5%. Heterogeneity was not reported; there was considerable variability across the studies.